Company News: Pfizer invests in Boston-area hospitals, Centron takes on OraPharma

Share this article:

Making good on its global initiative to bolster science and academia, New York-based pharma giant Pfizer has announced plans to invest $100 million with Boston's Longwood Medical Area. The investment will be made over the next five years and includes the establishment of a resource space – to be called the Center for Therapeutic Innovation – which will create about 50 new jobs. The aim of the company's partnership with Boston-area hospitals and med schools is to shorten the gaps that occur in the R&D stages of drug development.

Medical communications agency Centron has announced an account win with oral health company OraPharma. The agency will oversee medical communications responsibilities for Arestin, a localized antibiotic used in periodontics. “We're very excited to be chosen to guide development and execution of medical communications for Arestin,” said Marcia McLaughlin, President & CEO of Centron, in a release. “Our staff is ready to join the OraPharma team and deliver the strategic excellence we strive for every day.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.